[go: up one dir, main page]

MX2017002476A - Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. - Google Patents

Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.

Info

Publication number
MX2017002476A
MX2017002476A MX2017002476A MX2017002476A MX2017002476A MX 2017002476 A MX2017002476 A MX 2017002476A MX 2017002476 A MX2017002476 A MX 2017002476A MX 2017002476 A MX2017002476 A MX 2017002476A MX 2017002476 A MX2017002476 A MX 2017002476A
Authority
MX
Mexico
Prior art keywords
airway
methods
extracellular matrix
fibroblast proliferation
matrix deposition
Prior art date
Application number
MX2017002476A
Other languages
English (en)
Inventor
Lander Cynthia
Brophy Colleen
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of MX2017002476A publication Critical patent/MX2017002476A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

La invención descrita proporciona composiciones y métodos para tratar asma, una enfermedad, condición o proceso patológico, cuyo progreso se caracteriza por uno o más de la proliferación de fibroblasto aberrante y la deposición de matriz extracelular produciendo constricción en las vías respiratorias, remodelación de las vías respiratorias y obstrucción de las vías respiratorias, en el tejido pulmonar, El método incluye administrar una composición farmacéutica que comprende una cantidad terapéutica de un polipéptido que tiene la secuencia de aminoácidos YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) o equivalente funcional del mismo, y un portador farmacéuticamente aceptable, en donde la cantidad terapéutica del polipéptido es eficaz para reducir la constricción de las pequeñas dimensiones de las vías respiratorias y obstrucción de la vías respiratorias, tratar la remodelación de las vías respiratorias, o una combinación de éstos.
MX2017002476A 2014-08-29 2015-08-28 Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. MX2017002476A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/473,339 US9890200B2 (en) 2011-04-12 2014-08-29 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
PCT/US2015/047390 WO2016033432A1 (en) 2014-08-29 2015-08-28 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Publications (1)

Publication Number Publication Date
MX2017002476A true MX2017002476A (es) 2017-08-14

Family

ID=52583553

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002476A MX2017002476A (es) 2014-08-29 2015-08-28 Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.

Country Status (12)

Country Link
US (2) US9890200B2 (es)
EP (1) EP3185883A4 (es)
JP (1) JP2017528454A (es)
KR (1) KR20170044171A (es)
CN (1) CN107073075A (es)
AU (1) AU2015308761A1 (es)
BR (1) BR112017003731A2 (es)
CA (1) CA2958085A1 (es)
MX (1) MX2017002476A (es)
RU (1) RU2017110093A (es)
SG (1) SG11201701135WA (es)
WO (1) WO2016033432A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
HK1246807A1 (zh) * 2015-01-08 2018-09-14 Moerae Matrix, Inc. Mk2抑制剂肽的制剂
KR20170125090A (ko) * 2015-03-12 2017-11-13 모레 매트릭스 인코포레이티드 비-세포 폐암을 치료하기 위한 mk2 저해제 펩타이드-함유 조성물의 용도
CN112920256B (zh) * 2019-11-21 2022-08-19 上海医药工业研究院 一种治疗哮喘的生物肽及其应用
AU2023207395A1 (en) 2022-01-14 2024-07-11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
ES286422Y (es) 1982-10-08 1986-09-16 Glaxo Group Limited Dispositivo para administrar medicamentos a pacientes
SE8603252L (sv) 1985-07-30 1987-01-31 Glaxo Group Ltd Anordning for att tillfora lekemedel till patienter
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
DE69333955D1 (de) 1992-04-24 2006-02-02 Stanford Res Inst Int Targeting homologer sequenzen in eukaryotenzellen
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
JP3585238B2 (ja) 1993-12-09 2004-11-04 トーマス ジェファーソン ユニバーシティー 真核細胞における部位特異的突然変異誘発のための化合物および方法
ATE178046T1 (de) * 1994-02-17 1999-04-15 American Home Prod Substituierte biphenyl-derivate mit phosphodiesterase inhibierender wirkung
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
ES2261195T3 (es) 1999-04-05 2006-11-16 Mannkind Corporation Metodo de formacion de particulas finas.
ES2569916T3 (es) 1999-06-29 2016-05-13 Mannkind Corporation Formulaciones farmacéuticas que comprenden insulina complejada con una dicetopiperazina
KR20110017465A (ko) 2002-04-25 2011-02-21 더 스크립스 리서치 인스티튜트 폐질환 증상의 치료 및 예방
BR0312785A (pt) 2002-07-19 2005-08-30 Abbott Biotech Ltd Tratamento de desordens relacionadas a tnf(alfa)
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
ES2385934T3 (es) 2004-08-20 2012-08-03 Mannkind Corporation Catálisis de la síntesis de dicetopiperazina.
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
KR20070057829A (ko) 2004-08-23 2007-06-07 맨카인드 코포레이션 포스포디에스테라아제 5형의 억제제의 폐 전달
US7799344B2 (en) 2005-09-14 2010-09-21 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US8039431B2 (en) 2006-02-22 2011-10-18 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
TW200817047A (en) * 2006-04-03 2008-04-16 Teva Pharma Drug microparticles
CA2689296C (en) 2007-01-10 2015-11-17 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
US8063094B2 (en) 2007-02-08 2011-11-22 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
US20080282320A1 (en) 2007-05-11 2008-11-13 Denovo Andrew Security Compliance Methodology and Tool
ES2547229T3 (es) 2007-08-07 2015-10-02 Purdue Research Foundation Inhibidores de cinasa y usos de los mismos
BRPI0919759A2 (pt) 2008-10-20 2017-03-21 Moerae Matrix Inc polipeptídeos para tratamento e prevenção de adesões
AU2013202108B2 (en) * 2008-12-10 2015-12-24 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9327008B2 (en) 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US20110288036A1 (en) 2010-05-24 2011-11-24 Cynthia Lander Methods for Treating or Preventing Vascular Graft Failure
SG10201604560TA (en) 2011-04-12 2016-07-28 Moerae Matrix Inc Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Also Published As

Publication number Publication date
EP3185883A1 (en) 2017-07-05
RU2017110093A (ru) 2018-10-01
US10562947B2 (en) 2020-02-18
JP2017528454A (ja) 2017-09-28
EP3185883A4 (en) 2018-05-30
KR20170044171A (ko) 2017-04-24
US20180194817A1 (en) 2018-07-12
RU2017110093A3 (es) 2018-10-01
WO2016033432A9 (en) 2016-04-21
US9890200B2 (en) 2018-02-13
BR112017003731A2 (pt) 2017-12-05
AU2015308761A1 (en) 2017-02-23
SG11201701135WA (en) 2017-03-30
CN107073075A (zh) 2017-08-18
WO2016033432A1 (en) 2016-03-03
US20150064134A1 (en) 2015-03-05
CA2958085A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
MX359516B (es) Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.
NZ777871A (en) Small molecule modulators of il-17
MX2017006372A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular.
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2021002321A (es) Nuevos metodos.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
EA033113B1 (ru) Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта
MX2025009723A (es) Metodos de tratamiento contra adicciones
PH12017502087B1 (en) Tiotropium inhalation solution for nebulization
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
MX2020010738A (es) Formulaciones de ciclosporina para uso en el tratamiento del sindrome de bronquiolitis obliterante (bos).
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
NZ744942A (en) Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
EA202193276A1 (ru) Способы лечения холангиокарциномы
PH12019500841A1 (en) Nebulized tiotropium
EP4620940A3 (en) Synthesis of (+)-cannabinoids and their therapeutic effects
MX2019001320A (es) Composicion y uso de un peptido.